Roche Holding AG secured an option to exclusively develop and market Idorsia Ltd.'s oncology compounds as part of a research collaboration.

Roche will pay Idorsia an upfront payment of CHF15 million for the collaboration and can exclusively license compounds resulting from the collaboration and certain Idorsia compounds for a further payment of CHF35 million, after a pre-determined period.

Idorsia will also be eligible for one-time development and regulatory milestones of up to CHF410 million, sales-threshold based milestones and tiered royalties on annual net sales of all products resulting from the collaboration.

The companies will form a joint committee for the collaborative research, chaired by Idorsia.